Tatva Chintan Pharma Chem Reports Mixed Financial Results Amid Profitability and Liquidity Challenges in March 2025

Tatva Chintan Pharma Chem has reported its financial results for the quarter ending March 2025, revealing a complex picture of performance within the small-cap chemicals sector. The company achieved its highest quarterly net sales in the last five quarters, totaling Rs 107.86 crore, indicating a positive near-term sales trend. However, the financial results also highlight significant challenges.
The Profit After Tax (PAT) for the latest six months stands at Rs 1.17 crore, reflecting a substantial decline of 91.05% year on year. This trend suggests a concerning trajectory for profitability. Additionally, the Profit Before Tax (PBT), excluding other income, was recorded at Rs 1.31 crore, which represents a notable drop of 60.1% compared to the average PBT of the previous four quarters, indicating a negative near-term trend.

Furthermore, the company's cash and cash equivalents have reached their lowest point in the last six half-yearly periods at Rs 14.10 crore, signaling a deterioration in short-term liquidity. The Debtors Turnover Ratio has also declined to 4.64 times, the lowest in the last five half-yearly periods, suggesting a slowdown in the pace of settling debts.

Overall, Tatva Chintan's financial results reflect a mix of positive sales performance against a backdrop of significant profitability challenges and liquidity concerns.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.